Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.49 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.47 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.47 |
| ▸ | MME | P08473 | 10/20 | 0.46 |
| ▸ | ACE | P12821 | 8/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908566 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18059572 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18059571 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL609953 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL597164 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL24404055 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL18574633 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL598890 | 1.00 | GPR88 (0.49) | GPR88SRRPSAT1MMEACE | |
| Hydrochloric Acid SCHEMBL597844 | 0.99 | GPR88 (0.48) | GPR88SRRPSAT1MMEACE | |
| SCHEMBL7426879 | 0.99 | GPR88 (0.48) | GPR88SRRPSAT1MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2022-06-28 | — | — | US | disclosed |
| EP-3424899-B1 | SACUBITRIL INTERMEDIATE AND PREPARATION METHOD THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-05-11 | — | — | EP | disclosed |
| US-10479753-B2 | Sacubitril intermediate and preparation method thereof | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2019-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370739-B2 | Sacubitril intermediate and preparation method thereof | DPP4, ACE, DPP8 | GPR88 1950/4885SRR 1242/4885PSAT1 634/4885 |
| US-10479753-B2 | Sacubitril intermediate and preparation method thereof | ACE, DPP4, SI | GPR88 2233/4885SRR 1241/4885PSAT1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.